Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-31
2007-07-31
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S001000, C514S002600, C435S458000, C536S023100, C536S024200, C424S184100, C424S450000
Reexamination Certificate
active
09927422
ABSTRACT:
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or noncarrier.
REFERENCES:
patent: 4458006 (1984-07-01), Döenges et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5391723 (1995-02-01), Priest
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5629158 (1997-05-01), Uhlen
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5770434 (1998-06-01), Huse
patent: 5824812 (1998-10-01), Nantz et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6306405 (2001-10-01), O'Hagan et al.
patent: 6352975 (2002-03-01), Schreiner et al.
patent: 6355267 (2002-03-01), Collins
patent: 6458370 (2002-10-01), O'Hagan et al.
patent: 6465188 (2002-10-01), Gold et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6558670 (2003-05-01), Friede et al.
patent: 6559129 (2003-05-01), Kasid et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6589940 (2003-07-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 6737006 (2004-05-01), Grohman
patent: 6855492 (2005-02-01), O'Hagan et al.
patent: 6884435 (2005-04-01), O'Hagan et al.
patent: 6893821 (2005-05-01), Raz et al.
patent: 7129222 (2006-10-01), Van Nest et al.
patent: 7157437 (2007-01-01), Van Nest
patent: 7183111 (2007-02-01), Van Nest et al.
patent: 7186700 (2007-03-01), Standring et al.
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2002/0055477 (2002-05-01), Nest et al.
patent: 2003/0022852 (2003-01-01), Nest et al.
patent: 2003/0059773 (2003-03-01), Van Nest et al.
patent: 2003/0129251 (2003-07-01), Van Nest et al.
patent: 2003/0133988 (2003-07-01), Fearon et al.
patent: 2003/0175731 (2003-09-01), Fearon et al.
patent: 2003/0199466 (2003-10-01), Fearon et al.
patent: 2003/0216340 (2003-11-01), Van Nest et al.
patent: 2005/0037403 (2005-02-01), Krieg et al.
patent: 0 468 520 (1992-01-01), None
patent: 0 468 520 (1992-01-01), None
patent: 0468520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/04740 (1998-02-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/16804 (2000-03-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/54803 (2000-09-01), None
patent: WO 00/61161 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/00231 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/15726 (2001-03-01), None
patent: WO 01/22972 (2001-04-01), None
patent: WO 01/22990 (2001-04-01), None
patent: WO 01/35991 (2001-05-01), None
patent: WO 01/51500 (2001-07-01), None
patent: WO 01/54720 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68078 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/76642 (2001-10-01), None
patent: WO-03/015816 (2003-02-01), None
Lipford et al, Eur. J. Immunol., 1997, 27:2340-2344.
Aderem et al, Cell, 2000, 103:993-996.
Uhlmann et al, Current Opinion in Drug Discovery and Development, 2003, 6/2:204-217.
Gursel et al, J. Immunology, 2001, 167:3324-3328.
Plenat, Molecular Medicine Today, Jun. 1996, 1:250-257.
O'Hagan et al, Biomolecular Engineering, 2001, 18:69-85.
Ryan et al, Trends in Biotechnology, 2001, 19/8:293-304.
Maloy et al, Immunology, 1994, 81:661-667.
Krieg, Annual Review Immunology, 2002, 20:709-760.
Kofler et al, J. Immunological Methods, 1996, 192:25-35.
Manzel et al, Antisense and Nucleic Acid Drug Development, 1999, 9:459-464.
Nellore et al, J. Parenteral Science and Technology, 1992, 46/5:176-180.
Klinman et al, Immunological Reviews, 2001, 199:201-216.
Godard et al, Eur. J. Biochem., 1995, 232:404-410.
Singh et al, Nature Biotechnology, 1999, 17:1075-1081.
Weeratna et al, Vaccine, 2000, 18:1755-1762.
Horner et al, Cellular Immunology, 1998, 190:77-82.
Ponchel et al, Advanced Drug Delivery Reviews, 1998, 34:191-219.
O'Hagan et al, Vaccine, 2000, 18:1793-1801.
Kato et al, Biomaterials, 2003, 24:4253-4264.
O'Hagan et al, Vaccine, 2002, 20:3389-3398.
Kazzaz et al, J. Controlled Release, 2000, 67:347-356.
Lefeber et al, Infection and Immunity, Dec. 2003, 71/12:6915-6920.
Singh et al, PNAS, USA, 2000, 97/2:811-816.
Bhatt et al., Nucleosides & Nucleotides (1999) 18(6&7):1297-1299.
Fritz et al., Journal of Colloid and Interface Science (1997) 195:272-288.
Lewis et al., Journal of Drug Targeting (1998) 5(4):291-302.
Schwab et al., Proc. Natl. Acad. Sci. USA (1994) 91:10460-10464.
Agrawal, S. et al. (Feb. 2000). “Antisense Therapeutics: is it as Simple as Complementary Base Recognition?,”Molecular Med. Today6:72-81.
Busquets, M.A. et al. (Nov. 2003). “Peptides and Liposomes: From Biophysical to Immunogenic Studies,”Current Drug Targets4(8):633-642.
Crooke, S. T. (1998). “Basic Principles of Antisense Therapeutics,” Chapter 1In Antisense Research and Application,Crooke, S.T. ed., Springer-Verlag: Berlin, Germany, pp. 1-50.
Du Bois, R.M. (Oct. 21, 1999). “Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis,”New England Journal of Medicine341(17):1302-1304.
Fearon, K. et al. (2003). “A Minimal Human Immunostimulatory CpG Motif That Potently Induces IFN-γ and IFN-αProduction,”Eur. J. Immunol.33:2114-2122.
Fix, M. et al. (2002), “The Fluorosome™ Technique for Investigating Membrane On and Off- Loading of Drugs by β-CD and Sonicated SUV,”FEBS Letters516:109-112.
International Search Report mailed on Feb. 11, 2002 for PCT Application No. PCT/US01/07848 filed Mar. 12, 2001, three pages.
International Search Report mailed on Aug. 27, 2002 for PCT Application No. PCT/US01/25364 filed Aug. 13, 2001, four pages.
International Search Report mailed on Feb. 11, 2002 for PCT Application No. PCT/US01/07843 filed Mar. 12, 2001, three pages.
Li, Q.T. et al. (1993). “Effect of Cholesteryl Ester of the Distr
Dina Dino
Fearon Karen L.
Tuck Stephen
Van Nest Gary
Dynavax Technologies Corporation
Minnifield N. M.
LandOfFree
Biodegradable immunomodulatory formulations and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biodegradable immunomodulatory formulations and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biodegradable immunomodulatory formulations and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3770082